Pharmacy of the World – How India came to make one in five of the world’s generic medicines.
- $31.1bn pharmaceutical exports, FY26 (to more than 200 countries)
- ~20% of the world’s generics (by volume, the largest supplier)
- 47% of US generic prescriptions (filled with Indian-made medicine)
- ~670 US FDA-approved plants (the most outside the US)
About one in five pills taken anywhere on earth is made in India, and close to half of those filled in American pharmacies. On medicines, it is the rest of the world that depends on India.
India is third on earth by volume and about thirteenth by value, and that gap is the story: enormous share, thin margin. Exports reached $31.1bn in FY26, with the United States taking roughly 45% of them.
The same capability vaccinates the world: about 60% of UNICEF’s vaccines. At home, 19,000 Jan Aushadhi outlets sell the same molecules cheaply. The weak point is upstream: many of the active ingredients still come from China.
The signal to watch: Where the active ingredients come from. Volume built on imported intermediates is a supply chain, not a moat.
Where we would take your group
- Genome Valley, Hyderabad. Bulk drugs, vaccines and contract research in one cluster.
- Ahmedabad and Vadodara, Gujarat. US FDA-inspected lines filling American pharmacy shelves.
- A Jan Aushadhi Kendra, any city. The same molecules, priced for an Indian household.
Questions for the debrief
- India makes a fifth of the world’s medicine by volume and a small fraction of it by value. How much of that gap is a strategic choice, and how much is a ceiling?
- Nearly half of America’s generic prescriptions depend on plants your students will never see. What does that concentration mean for resilience, and who should pay for redundancy?
- The cost advantage rests partly on Chinese intermediates. If that supply were interrupted, which of your own sectors would feel it first?
